CA2662843A1 - Identification of cancer stem cells using genetic markers - Google Patents
Identification of cancer stem cells using genetic markers Download PDFInfo
- Publication number
- CA2662843A1 CA2662843A1 CA002662843A CA2662843A CA2662843A1 CA 2662843 A1 CA2662843 A1 CA 2662843A1 CA 002662843 A CA002662843 A CA 002662843A CA 2662843 A CA2662843 A CA 2662843A CA 2662843 A1 CA2662843 A1 CA 2662843A1
- Authority
- CA
- Canada
- Prior art keywords
- expression
- cancer
- slug
- ovol1
- ovol2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 205
- 201000011510 cancer Diseases 0.000 title claims abstract description 196
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 111
- 230000002068 genetic effect Effects 0.000 title description 3
- 230000014509 gene expression Effects 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 99
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 101100242392 Homo sapiens OVOL2 gene Proteins 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 238000003745 diagnosis Methods 0.000 claims abstract description 12
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 claims description 128
- 102100026326 Putative transcription factor Ovo-like 1 Human genes 0.000 claims description 83
- 101001121409 Homo sapiens Transcription factor Ovo-like 2 Proteins 0.000 claims description 61
- 102100026385 Transcription factor Ovo-like 2 Human genes 0.000 claims description 61
- 101001121371 Homo sapiens Putative transcription factor Ovo-like 1 Proteins 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 101150012407 OVOL1 gene Proteins 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 24
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 108700008625 Reporter Genes Proteins 0.000 claims description 11
- 238000003384 imaging method Methods 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 7
- 238000009739 binding Methods 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000008029 eradication Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 230000001902 propagating effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 106
- 241000699670 Mus sp. Species 0.000 description 40
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 28
- 210000005259 peripheral blood Anatomy 0.000 description 28
- 239000011886 peripheral blood Substances 0.000 description 28
- 108010011042 Envoplakin Proteins 0.000 description 27
- 102100027253 Envoplakin Human genes 0.000 description 27
- 101150047834 SNAI2 gene Proteins 0.000 description 19
- 208000026310 Breast neoplasm Diseases 0.000 description 18
- 239000000090 biomarker Substances 0.000 description 17
- 206010006187 Breast cancer Diseases 0.000 description 15
- 201000008275 breast carcinoma Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000001394 metastastic effect Effects 0.000 description 10
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 229940080856 gleevec Drugs 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000005296 lung carcinoma Diseases 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- -1 LMOI Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102100023876 Rhombotin-2 Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 2
- 238000003314 affinity selection Methods 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000003888 major urinary proteins Human genes 0.000 description 2
- 108090000280 major urinary proteins Proteins 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 101150074953 BCL10 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010058545 Cyclin D3 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700037122 EWS-FLI fusion Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100029234 Histone-lysine N-methyltransferase NSD2 Human genes 0.000 description 1
- 101710196680 Histone-lysine N-methyltransferase NSD2 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000578353 Homo sapiens Nodal modulator 2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 101150113681 MALT1 gene Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 description 1
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100027967 Nodal modulator 2 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 description 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710096632 Rhombotin-2 Proteins 0.000 description 1
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100023234 Transcription factor MafB Human genes 0.000 description 1
- 108050003944 Transcription factor MafB Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000017047 asymmetric cell division Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 108091000099 cysteine desulfurase Proteins 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000043134 snail C2H2-type zinc-finger protein family Human genes 0.000 description 1
- 108091054456 snail C2H2-type zinc-finger protein family Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06018771.3 | 2006-09-07 | ||
| EP06018771 | 2006-09-07 | ||
| PCT/IB2007/003648 WO2008029290A2 (en) | 2006-09-07 | 2007-09-07 | Identification of cancer stem cells using genetic markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2662843A1 true CA2662843A1 (en) | 2008-03-13 |
Family
ID=39157635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002662843A Abandoned CA2662843A1 (en) | 2006-09-07 | 2007-09-07 | Identification of cancer stem cells using genetic markers |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100034736A1 (enExample) |
| EP (1) | EP2059613A2 (enExample) |
| JP (1) | JP2010502210A (enExample) |
| CA (1) | CA2662843A1 (enExample) |
| WO (1) | WO2008029290A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196905A1 (en) * | 2009-01-30 | 2010-08-05 | Kci Licensing, Inc. | Adult Stem Cell Assays |
| KR101231235B1 (ko) | 2010-04-21 | 2013-02-08 | 고려대학교 산학협력단 | 전립선암 줄기세포 선별용 단백질성 마커 |
| KR101240199B1 (ko) | 2010-04-26 | 2013-03-06 | 고려대학교 산학협력단 | 대장암 줄기세포 선별용 단백질성 마커 |
| HRP20200961T1 (hr) * | 2011-07-21 | 2020-10-02 | Menarini Silicon Biosystems S.P.A. | Test za hvatanje i detektiranje cirkulirajućih stanica multiplog mijeloma iz krvi |
| CN103151461A (zh) | 2013-02-27 | 2013-06-12 | 京东方科技集团股份有限公司 | 一种有机薄膜晶体管及其制备方法和制备装置 |
| ES2651522T3 (es) * | 2013-12-16 | 2018-01-26 | Humanitas Mirasole S.P.A. | Altos niveles de FT de TEM para el diagnóstico del cáncer, en particular de cáncer colorrectal (CCR) y de páncreas (CP) |
| KR101805181B1 (ko) | 2016-09-02 | 2017-12-07 | 충북대학교 산학협력단 | 인산화된 slug 단백질의 유사분열 세포에 대한 신규한 바이오 마커로서의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2195751B1 (es) * | 2001-11-27 | 2005-04-01 | Universidad De Salamanca (Otri) | Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem. |
| CA2469204A1 (en) * | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| WO2003058201A2 (en) * | 2001-12-31 | 2003-07-17 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1530418A4 (en) * | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS |
| US20040170605A1 (en) * | 2003-02-27 | 2004-09-02 | Garcia Isidro Sanchez | Use of the slug gene as a genetic marker in functions mediated by SCF (stem cell factor) and applications |
| US7927795B2 (en) * | 2003-06-09 | 2011-04-19 | Board Of Trustees Of The University Of Arkansas | Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| JP2005000056A (ja) * | 2003-06-11 | 2005-01-06 | Sumitomo Pharmaceut Co Ltd | ホルモン依存性癌疾患マーカー及びその利用 |
| WO2006002378A2 (en) * | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| ES2301268B1 (es) * | 2004-10-25 | 2009-05-01 | Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. | Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis. |
| CA2629330C (en) * | 2004-11-12 | 2018-05-22 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2007
- 2007-09-07 EP EP07825743A patent/EP2059613A2/en not_active Withdrawn
- 2007-09-07 CA CA002662843A patent/CA2662843A1/en not_active Abandoned
- 2007-09-07 US US12/440,369 patent/US20100034736A1/en not_active Abandoned
- 2007-09-07 JP JP2009527228A patent/JP2010502210A/ja active Pending
- 2007-09-07 WO PCT/IB2007/003648 patent/WO2008029290A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20100034736A1 (en) | 2010-02-11 |
| EP2059613A2 (en) | 2009-05-20 |
| WO2008029290A2 (en) | 2008-03-13 |
| WO2008029290A3 (en) | 2008-07-17 |
| JP2010502210A (ja) | 2010-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kasimir-Bauer et al. | Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells | |
| Mego et al. | Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy | |
| Janni et al. | Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer | |
| Damm-Welk et al. | Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphoma | |
| Fehm et al. | Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance | |
| Falcone et al. | Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series | |
| EP2003196A2 (en) | Compositions and methods for treating and diagnosing cancer | |
| US20100034736A1 (en) | Identification of cancer stem cells using genetic markers | |
| Wang et al. | Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia | |
| Maragkou et al. | Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas | |
| Attarbaschi et al. | Mixed Lineage Leukemia–rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity | |
| WO2008130568A1 (en) | Compositions and methods for treating and diagnosing cancer | |
| Huang et al. | Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes | |
| Osman et al. | Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients | |
| Zhao et al. | Comparative analysis of flow cytometry and RQ-PCR for the detection of minimal residual disease in philadelphia chromosome–positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation | |
| Hwang et al. | Circulating cancer stem cells expressing EpCAM/CD90 in hepatocellular carcinoma: a pilot study for predicting tumor recurrence after living donor liver transplantation | |
| Perez-Lanzon et al. | New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma | |
| Virk et al. | Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort | |
| Li et al. | Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma | |
| WO2009013614A2 (en) | Marker gene | |
| Hu et al. | The emerging role of minimal residual disease testing in diffuse large B-cell lymphoma | |
| Williamson et al. | Human α2β1HI CD133+ VE epithelial prostate stem cells express low levels of active androgen receptor | |
| Lüke et al. | Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment | |
| US9388469B2 (en) | Sox11 expression in malignant lymphomas | |
| US20150017638A1 (en) | Methods for assessing risk for cancer using biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |